Glycopeptide antibiotic combination therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Clostridium difficile infections using broad-spectrum antibiotics disrupt the gut microbiota, leading to increased recurrence of infections and damage to beneficial bacteria.
Innovation Solution
A combination therapy using glycopeptide antibiotics, each at concentrations below their minimal inhibitory concentration, synergistically inhibits C. difficile while sparing the gut microbiota, utilizing a first glycopeptide antibiotic like keratinicyclin B and a second glycopeptide antibiotic such as vancomycin to target specific and broad-spectrum bacteria respectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum antibiotics are used to treat C. difficile infections, then the infection is effectively treated, but the gut microbiota is disrupted leading to increased recurrence
Solution Approach 1:
The patent segments the antibiotic treatment approach by using multiple different glycopeptide antibiotics (at least three distinct agents) instead of a single broad-spectrum antibiotic. Each antibiotic targets C. difficile through different mechanisms or pathways, allowing effective treatment while reducing disruption to beneficial gut bacteria compared to conventional single-agent therapy
Solution Approach 2:
The patent changes the concentration parameter by administering each glycopeptide antibiotic at concentrations below its individual minimal inhibitory concentration (MIC) for C. difficile. This sub-MIC dosing strategy, when combined with multiple agents, achieves synergistic inhibition of C. difficile while minimizing harm to gut microbiota, representing a fundamental parameter change from conventional full-MIC dosing
2Reliability
If higher concentrations of single antibiotic are used to ensure complete inhibition, then treatment reliability improves, but damage to beneficial bacteria increases
Solution Approach 1:
The patent merges multiple glycopeptide antibiotics into a combination therapy regimen. By combining at least three different glycopeptide agents, each at sub-MIC concentrations, the treatment achieves complete inhibition of C. difficile through synergistic effects while each individual agent operates at lower concentrations that are less harmful to beneficial gut bacteria
Solution Approach 2:
The patent creates a composite antibiotic regimen using multiple glycopeptide agents with different structures and mechanisms of action. This composite approach (analogous to composite materials in engineering) allows the treatment to achieve the antimicrobial efficacy of high-dose single agents while reducing the toxic effects on beneficial microbiota through the distributed, lower-dose multi-agent strategy
Data Source
AI summary
Bacterial infections evading the current antibiotic arsenal warrant new treatment options. The mainstay treatment for Clostridium difficile infections involves administration of the broad-spectrum antibiotic vancomycin, which also depletes the gut microbiome and its natural defenses. This leads to recurrent C. difficile infections in 20-30% of patients. Alternative treatment options are limited, triggering a perpetual cycle of relapse and recovery that may eventually lead to death. Keratinicyclin B represents a glycopeptide antibiotic chemotype with a mechanism of action that is selective for Clostridia. When combined, vancomycin (or other glycopeptide antibiotic) and keratinicyclin B interact synergistically to inhibit the growth of C. difficile at concentrations far lower than their respective minimal inhibitory concentrations. Such a combination therapy could allow for targeted colonization clearance at low antibiotic doses, thereby minimizing toxicity and reducing the likelihood of relapse.